





Konica Minolta, Inc. 1st Quarter/FY2018 ending in March 2019 Consolidated Financial Results

Three months: April 1, 2018 – June 30, 2018 – Announced on August 1, 2018 –

Seiji Hatano Senior Executive Officer Chief Financial Officer Konica Minolta, Inc.

FY2018 1Q Financial Performance | summary



| | FY2018 1Q | FY2017 1Q | YoY | YoY (W/O Forex) | |
|--|--------------|--------------|-------|--------------------|--|
| Revenue | 255.2 | 232.4 | +10% | + 9% | |
| Operating Profit | 15.4 | 8.7 | +77% | + 46% | |
| Profit attributable to owners of the company | 11.2 | 5.4 | +108% | | |
| | | | | | |
| FOREX [Yen] | | | | | |
| USD | 109.07 | 111.09 | - 2% | | |
| Euro | 130.06 | 122.19 | +6% | | |


| Revenue | Office Business revenue grew in all regions, and Professional Print Business also posted higher revenue, driven by Europe and China. Healthcare Business was affected by discontinuing the selling of certain purchased products, resulting in lower revenue. Industrial revenue increased with higher sales of Performance Materials, offsetting declines in sales caused by a slowing of demand in the Measuring Instruments business unit. |
|---------------------|---|
| Operating profit | Due to strengthening of profitability in core businesses, all business segments recorded growth in profits, in addition to which measures to liquidate assets through sale and lease back also generated income, leading to a significant year-on-year increase in profit for the Group as a whole. |



| Revenue | FY2018 | FY2017 | YoY | YoY |
|------------------------------------|--------|--------|-------|-------------|
| | 1Q | 1Q | 101 | (W/O Forex) |
| Office | 143.5 | 133.0 | +8% | +6% |
| Professional Print | 53.4 | 49.0 | +9% | +8% |
| Healthcare | 18.6 | 19.5 | -5% | -5% |
| Industrial | 31.6 | 28.7 | +10% | +10% |
| Optical systems for industrial use | 10.1 | 11.7 | -14% | -15% |
| Materials and components | 21.5 | 17.0 | +26% | +28% |
| New business | 7.8 | 1.9 | +304% | +298% |
| Bio-healthcare | 5.9 | 0.0 | — | _ |
| Others | 2.0 | 1.9 | +2% | +2% |
| Corporate, etc. | 0.3 | 0.1 | +111% | +95% |
| Company overall | 255.2 | 232.4 | +10% | +9% |

| Operating profit/OPM | FY20 10 | | FY2017 1Q | YoY | YoY (W/O Forex) |
|----------------------|------------|---------|--------------|------|--------------------|
| Office | 9.3 | 6.5% | 5.3 | +73% | +30% |
| Professional Print | 1.7 | 3.1% | 1.6 | +6% | -24% |
| Healthcare | -0.2 | -1.1% | -0.5 | - | - |
| Industrial | 6.8 | 21.4% | 6.1 | +11% | +15% |
| New business | -5.1 | -65.1% | -2.7 | - | - |
| Corporate, etc. | 3.1 | 1012.7% | -1.1 | — | - |
| Company overall | 15.4 | 6.1% | 8.7 | +77% | +46% |





* BF: Business Factors; OP: Operating Profit; ESF: External and Special Factors

FY2018 1Q Performance | Structural Reform and CRE Strategy




- Promotion of structural reforms in Japan and overseas continues as part of the strengthening of profitability in core businesses set out in Medium Term Business Plan SHINKA 2019.
- Implemented sale & lease back as part of corporate real estate (CRE) strategy, expenses related to repairs/removals, etc. also arose.
- As of June 27, the Company concluded sale and lease back contracts for ownership of the land on its Tokyo sites (Hachioji and Hino), posting ¥9.5 billion in 1Q, with the remaining ¥10.6 billion to be recorded in 2Q and beyond.

| 7 | | Impact or | n profit and loss | | |
|--------------------------------------|---|-----------|-------------------|--|---|
| | | FY17 1Q | FY17 12M | FY18 1Q | FY18 12M |
| (1) Structural reform expenses | Special early retirement program in Japan, consolidation of warehouses/outsourcing of back-office in Europe, consolidation of locations in North America, etc. | -¥0.8 bn | -¥10.0 bn | –¥0.7 bn | -¥2.0bn to -¥3.0 bn |
| (2) CRE strategy | Global optimization of facilities use (land/buildings) | ¥4.0 bn | ¥20.9 bn | ¥8.4 bn (S&LB ¥9.5 bn, repairs, etc. ¥1.1 bn) | ca. ¥13.0 bn (S&LB ¥20.1 bn, repairs, etc.) |
| (1)+(2) Total of one-off profit | | ¥3.2 bn | ¥10.9 bn | ¥7.7 bn | ¥10.0 bn to ¥11.0 bn |



| Revenue | Operating Profit | 1Q Summary |
|--|---------------------------------|--|
| | [¥ billions] | Office |
| IT Service Solution Office YoY+8% 143.5 | | Color sales volumes grew in Europe, primarily high-speed models, and monochrome sales also rose, leading to significant increase. In North America also, sales rose, mostly for high-speed color models. In China, India, and ASEAN countries, there was significant |
| 133.0 17.9 _{YoY+} | +17% | growth in color models from low-speed to high-speed. Partner sales also grew considerably. |
| 15.2 | YoY+73% 6. <mark>5% 9</mark> | Progress was made in line with Company regional strategy, and although monochrome models declined overall, sales volumes of full-color model rose significantly, and overall A3 MFP sales volumes increased. |
| 117.8 125.7 YoY+ | 9.3 4.0% • 9.3 5.3 | IT Services Solutions In the US, in addition to the continued impact of newly consolidated subsidiaries, sales of security solutions, etc. made contributions. In Europe, sales of managed content services with improved margins continued to rise due to enhancements to service |
| FY17 FY18 1Q 1Q | FY17 FY18 1Q 1Q | system. |






Office

• Significant growth centered on color 65/75 ppm models particularly in Europe and all regions, e.g. North America, Japan, China, India, ASEAN are also extending.


Year-on-year growth rate in A3 color MFP shipments



Production Print

- Attractive value proposition of AccurioPress C6100 series and IQ-501 have led to improved profitability
- Growth in sales volumes in Europe and China has been especially strong


Year-on-year growth rate in Production Print color models





| Reve | enue | Operati | ng Profit | 1Q Summary |
|---|---|------------------|--------------------------------|---|
| Medical | IT | | [¥ billions] | Healthcare (Modality) |
| Healthca 19.5 1.5 | Are (Modality) YoY-5% 18.6 1.6 YoY | (+12% FY17 1Q | FY18 1Q -0.2 | DR: was strong in both Japan and the US. In the US, sales of integrated X-ray system products grew, in addition to sales of stand-alone DR products. Ultrasound: significant growth in US, China. In Japan, obstetrics and gynecology business acquired from Siemens Healthcare K.K. in the previous fiscal year also made progress. Impact of discontinuing selling of certain purchased products resulted in lower revenue. |
| 18.1 | 17.0 YoY | | YoY- 0 - 1.1% | Medical IT In Japan, won major contracts related to hospitals. Service contract revenue also rose steadily. |
| FY17 1Q | FY18 1Q | | | |










FY17

1Q

FY18

1Q







FY18

1Q

FY17


1Q



Measuring Instruments

- In addition to the following wind of technological innovation in mobile equipment, customer base expansion has been successful. There was a rise in the level of quarterly sales.
- YoY: revenue -13%
- QoQ: revenue +23%


Measuring Instruments revenue (¥ billions)



Performance Materials

- The strategic shift to such high value-added products has borne fruit, and the trend of higher revenue has continued from FY17 3Q against the backdrop of the move to larger TVs.
- YoY: revenue +42%
- QoQ: revenue +11%


Net sales of Performance Materials (¥ billions)





| Reve | nue | 1Q Summary |
|--------------|--------------|---|
| | [¥ billions] | Genetic diagnostics (Ambry) |
| Bio-healthca | re QoQ+8% | As a result of a strengthening sales structure, the number of samples is increasing. Fundamental improvements are being made to the insurance reimbursement process, and review of the testing menu is complete. As a strategy to open the specialist cancer doctor channel, have concluded business alliance agreements with industry peers. As a stepping stone to develop the drug discovery/support business, have won a clinical trials project with a major pharmaceutical company, with growing pipelines. |
| | | Drug discovery/support (Invicro) |
| 5.4 | 5.9 | Pipeline has exceeded forecasts on a value basis, and we are building a sales & marketing structure to maintain and ensure sufficient pipeline going forward. Completed technical introduction of HSTT, beginning joint proposals. |
| | | Domestic expansion |
| FY17 4Q | FY18 1Q | Preparations for the expansion of the genetic diagnostics and drug discovery/support business are proceeding on schedule, and the hiring of the management team has been completed. |






* Since FY2018, including Ambry and Invicro



[¥ billions] **Equity & Equity Ratio** Attributable to owners of the parent company Despite the decline in the equity ratio caused by borrowing the funds necessary for the acquisition of the bio-healthcare business in FY2017, utilizing hybrid loans allowed us to maintain our credit rating at "A". Shareholders' equity 533.3 525.7 524.3 524.5 514.3 52.7 53. 52.1 43.6 44 3 168.3 0.130.33 Mar Mar Mar Jun Jun 2018 2018 2016 2017 2017 Mar (For Company Rating 48.3%) Equity = Equity attributable to owners of the company 2016 Equity ratio = Equity attributable to owners of the company / Total assets

Interest-Bearing Debts & [¥ billions] D/E Ratio

Interest-bearing debts increased due to hybrid loan borrowings, resulting in higher debt-toequity and net debt equity ratios.





| | FY2018 12M | FY2018 12M | FY2017 12M | | |
|--|-----------------------|------------------------|------------|------|--|
| | Forecast (current) | Forecast (previous) | Results | YoY | |
| Revenue | 1,080.0 | 1,080.0 | 1,031.3 | +5% | |
| Operating Profit | 62.0 | 60.0 | 53.8 | +15% | |
| Profit attributable to owners of the company | 38.5 | 37.0 | 32.2 | +20% | |
| | | | | | |
| FOREX [Yen] USD | 105.0 | 105.0 | 110.9 | | |
| Euro | 125.0 | 125.0 | 129.7 | | |

Full-year earnings forecast
 Euro and US\$ assumptions unchanged at ¥125 and ¥105, respectively.
 Net sales: left unchanged, given progress at the quarterly level.
 Operating profit : having taken into account that 1) asset liquidations through sale and lease back are exceeding assumptions set at the beginning of the fiscal year; 2) the rising probability that results will meet forecasts as a result of strengthened profitability in core businesses; and 3) the economic uncertainty caused by the US-China trade dispute, etc., we have revised the forecast upward by ¥2.0 billion.
 Annual dividend: Unchanged at ¥30 per share (¥15 for both interim and period-end).

Appendix



| | FY2018 | FY2017 | |
|--|---------------|--------------|--------|
| | 1Q | 1Q | YoY |
| Revenue | 255.2 | 232.4 | + 10% |
| Gross Profit | 123.7 | 112.0 | + 10% |
| Gross Profit ratio | <i>48.5</i> % | <i>48.2%</i> | _ |
| Operating Profit | 15.4 | 8.7 | + 77% |
| Operating Profit ratio | <i>6.1%</i> | 3.8% | - |
| Profit before tax | 15.3 | 8.2 | + 86% |
| Profit before tax ratio | <i>6.0</i> % | 3.5% | - |
| Profit attributable to owners of the company | 11.2 | 5.4 | + 108% |
| Profit attributable to owners of the company ratio | 4.4% | 2.3% | - |
| EPS [Yen] | 22.61 | 10.83 | |
| CAPEX | 8.6 | 8.2 | + 5% |
| Depreciation and Amortization Expenses | 14.6 | 13.6 | + 7% |
| R&D expenses | 20.4 | 18.5 | + 10% |
| FCF | -0.4 | -8.6 | - |
| Investment and lending | 3.0 | 0.6 | |
| FOREX [Yen] USD | 109.07 | 111.09 | -2.02 |
| euro | 130.06 | 122.19 | +7.87 |



| SG&A: | FY2018 1Q | FY2017 1Q | YoY |
|---|------------------|---------------------|-------|
| Selling expenses – variable | 12.0 | 11.2 | +0.8 |
| R&D expenses | 20.4 | 18.5 | +1.9 |
| Personnel expenses | 52.9 | 48.6 | +4.3 |
| Others | 29.9 | 27.8 | +2.1 |
| SG&A total | 115.3 | 106.1 | +9.2 |
| * Forex impact: | +1.2bn. (Actual. | : + 8.0bn.) | |
| Other income: | | | |
| Gain on sales of property, plant and equipment | 9.6 | 4.0 | +5.6 |
| Other income | 0.5 | 0.8 | - 0.3 |
| Other income total | 10.1 | 4.8 | +5.3 |
| Other expenses | | | |
| Loss on sales of property, plant and equipment | 1.3 | 0.1 | +1.1 |
| Special extra retirement payments | - | 0.5 | - 0.5 |
| Other expenses | 1.8 | 1.3 | +0.5 |
| Other expenses total | 3.0 | 2.0 | +1.0 |
| Finance income/loss: | | | |
| Interest income/Dividends received/Interest expense | -0.1 | 0.1 | - 0.2 |
| Foreign exchange gain/loss (net) | 0.3 | -0.4 | +0.7 |
| Others | -0.3 | -0.1 | - 0.2 |
| Finance income/loss, net | - 0.0 | -0.4 | +0.4 |



FY2018/1Q vs FY2017/1Q

| | Office | Professional Printing | Healthcare | Industrial Business | New business | corporate, etc. | Total |
|-------------------------------------|--------|--------------------------|------------|------------------------|--------------|--------------------|-------|
| [Factors] | | | | | | | |
| Forex impact | 2.4 | 0.5 | 0.1 | -0.3 | -0.0 | 0.0 | 2.7 |
| Price change | -1.2 | 0.3 | -0.2 | -0.5 | 0.0 | 0.0 | -1.6 |
| Sales volume change, and other, net | 3.2 | 0.9 | -0.2 | 1.6 | 2.9 | -0.0 | 8.3 |
| Cost up/down | 0.6 | 0.1 | 0.2 | 0.2 | -0.0 | 0.0 | 1.0 |
| SG&A change, net | -1.0 | -1.9 | 0.4 | -0.1 | -5.3 | -0.2 | -8.0 |
| Other income and expense | -0.1 | 0.2 | -0.0 | -0.2 | 0.1 | 4.4 | 4.3 |
| [Operating Profit] | | | | | | | |
| Change, YoY | 3.9 | 0.1 | 0.3 | 0.7 | -2.4 | 4.2 | 6.7 |



[¥ billions] Capital Expenditure and Free Cash Flows **Depreciation and Amortization Expenses** INC FCF Capital expenditures Depreciation and amortization Net cash flows from investing activities Net cash flows from operating activities *Portion invested by INCJ 60.0 at time of AG 52.6 56.3 55.0 acquisition 51.8 47.9 51.3 46.1 * 35.4 38.9 38.7 48.0 35.0 133.7 110.8 70.6 102.0 90.0 68.7 65.4 59.2 54.0 55.0 -1.9FY2018 FY2018 FY2016 FY2014 FY2016 FY2014 FY2015 -33.0 FY2017 Forecast Forecast -51.5 FY2017 FY2015

INCJ : Innovation Network Corporation of Japan

*FCF forecast for FY2018 does not include investment and lending



| | FY2018 12M | FY2018 12M | FY2017 12M | |
|--|-------------------|--------------------|------------|-------|
| | Forcast (current) | Forcast (previous) | Results | YoY |
| Revenue | 1,080.0 | 1,080.0 | 1,031.3 | + 5% |
| Operating Profit | 62.0 | 60.0 | 53.8 | + 15% |
| Operating Profit ratio | 5.7% | 5.6% | 5.2% | |
| Profit before tax | 57.0 | 55.0 | 49.1 | + 16% |
| Profit attributable to owners of the company | 38.5 | 37.0 | 32.2 | + 20% |
| Profit attributable to owners of the company ratio | 3.6% | 3.4% | 3.1% | |
| EPS [Yen] | 77.85 | 74.82 | 65.17 | |
| ROE* (%) | 7.2% | 6.9% | 6.1% | |
| CAPEX | 55.0 | 55.0 | 38.7 | |
| Depreciation and Amortization Expenses | 60.0 | 60.0 | 56.3 | |
| R&D expenses | 80.0 | 80.0 | 77.0 | |
| FCF | 35.0 | 35.0 | -68.4 | |
| Investment and Ioan | 30.0 | 30.0 | 125.0 | |
| | | | | |
| FOREX [Yen] USD | 105.00 | 105.00 | 110.90 | |
| EUR | 125.00 | 125.00 | 129.70 | |

ROE*: Profit attributable to owners of the company divided by equity attributable to owners of the company (average of beginning and ending balances)

*) -33.0 without contribution from INCJ for acquisition of Ambry Genetics Corporation



| | FY2018 | FY2018 | FY2017 | |
|------------------------------------|---------------------------|----------------------------|-------------|--------|
| Revenue | 12M Forecast (current) | 12M Forecast (previous) | 12M Results | YoY |
| Office | 585.0 | 585.0 | 583.9 | + 0% |
| Professional Printing | 232.5 | 232.5 | 214.3 | + 9% |
| Healthcare | 92.5 | 92.5 | 96.5 | - 4% |
| Industrial | 120.0 | 120.0 | 118.2 | + 1% |
| Optical systems for industrial use | 40.0 | 40.0 | 43.1 | - 7% |
| Materials and components | 80.0 | 80.0 | 75.1 | + 6% |
| New business | 50.0 | 50.0 | 17.3 | + 188% |
| Bio-Healthcare | 35.0 | 35.0 | 9.0 | + 290% |
| Others | 15.0 | 15.0 | 8.4 | + 79% |
| Corporate, etc. | 0.0 | 0.0 | 1.0 | - |
| Company overall | 1,080.0 | 1,080.0 | 1,031.3 | + 5% |

| | FY2018 | FY2018 | FY2017 | |
|-----------------------|---------------------------|-------------------|------------|-------|
| Operating Profit | 12M Forecast (current) | 12M Results | | YoY |
| Office | 45.0 7.7% | 45.0 <i>7.7</i> % | 44.9 7.7% | + 0% |
| Professional Printing | 12.5 5.4% | 12.5 5.4% | 9.3 4.3% | + 35% |
| Healthcare | 5.0 5.4% | 5.0 <i>5.4%</i> | 5.6 5.8% | - 10% |
| Industrial | 19.0 <i>15.8%</i> | 19.0 <i>15.8%</i> | 23.5 19.8% | - 19% |
| New business | -11.5 | -11.5 | -16.0 | - |
| Corporate, etc. | -8.0 | -10.0 | -13.4 | - |
| Company overall | 62.0 5.7% | 60.0 5.6% | 53.8 5.2% | + 15% |

Appendix Revenue and Operating Profit



[FOREX : ¥] [Impact, Sensitivity : ¥ billions]

| | FY17 | FY18 | Impact t | o 2016 | FX Sensi | tivity*2 |
|-----------------------------|--------|--------|----------|--------|----------|----------|
| | 1Q | 1Q | Revenue | OP | Revenue | OP |
| USD | 111.09 | 109.07 | -1.8 | 0.1 | 3.3 | 0.0 |
| EUR | 122.19 | 130.06 | 3.4 | 2.3 | 1.8 | 0.7 |
| GBP | 142.00 | 148.55 | 0.5 | - 0.0 | 0.3 | 0.1 |
| European Currency*1 | - | - | 4.2 | 2.2 | 2.6 | 1.1 |
| CNY | 16.21 | 17.13 | 0.7 | 0.1 | 3.0 | 1.0 |
| AUD | 83.42 | 82.59 | -0.1 | -0.1 | 0.4 | 0.1 |
| Other | _ | _ | -0.1 | -0.2 | _ | _ |
| Exchange contract effect | | _ | 0.0 | 0.4 | | _ |
| Total impact from FY2018 | _ | _ | 2.9 | 2.7 | _ | _ |

*1 European currency: Currencies used in Europe excluding EUR/GBP

*2 FOREX Sensitivity: FOREX impact at ¥1 change (annual)


Appendix ROE / Shareholder Returns



<u>ROE</u>


ROE1: profit for the year attributable to the owners of the company, divided by the average (using figures from start and end of year) of the sum of share capital, share premium, retained earnings and treasury shares

ROE2: profit attributable to owners of the company divided by equity attributable to owners of the company (average of beginning and ending balances)



Shareholder Returns







Composition of revenue by region (in yen)

| | | FY201 | 6 | | | FY201 | 7 | | FY2018 |
|---------------|-----|-------|-----|-----|-----|-------|-----|-----|--------|
| | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q |
| Japan | 13% | 12% | 13% | 13% | 13% | 13% | 12% | 12% | 13% |
| North America | 32% | 34% | 33% | 32% | 34% | 34% | 33% | 31% | 33% |
| EU | 37% | 36% | 36% | 38% | 36% | 36% | 38% | 40% | 36% |
| Others | 18% | 18% | 18% | 16% | 17% | 17% | 17% | 17% | 18% |

Change in revenue by region (w/o FOREX)

| | | FY2016 | | | FY2017 | | | | FY2018 |
|---------------|-------|--------|--------|-------|--------|-------|-------|-------|--------|
| | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q |
| Japan | -1.0% | -1.0% | -1.0% | -2.0% | +2.0% | +0.0% | -1.0% | -1.0% | +4.5% |
| North America | +2.0% | +3.0% | +6.0% | -3.0% | +2.0% | +3.0% | -3.0% | +8.0% | +5.4% |
| EU | +4.0% | +4.0% | +9.0% | +4.0% | -1.0% | +2.0% | +1.0% | +4.0% | +4.2% |
| Others | +4.0% | +7.0% | -12.0% | -1.0% | -10.0% | -8.0% | -5.0% | -2.0% | +16.1% |

Percentage of color in sales of hardware

| | | FY2016 | | | | FY2017 | | | |
|--------------------|-----|--------|-----|-----|-----|--------|-----|-----|-----|
| | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q |
| Office | 71% | 72% | 72% | 72% | 69% | 72% | 72% | 72% | 73% |
| Professional Print | 74% | 73% | 73% | 72% | 78% | 76% | 80% | 78% | 81% |








A3 B&W MFP- Units*



A3 MFP- Units*




Color Production Print – Units*



B&W Production Print – Units*




Production Print – Units* YoY: +8%



Appendix Sales Results for Non-Hard | Office/Professional Print







| | | | | | | | | | [¥ billions] |
|------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|--------------|
| | | FY16 | | | | FY17 | | FY18 | [] |
| [Revenue] | 1Q | 2Q | ЗQ | 4Q | 1Q | 2Q | ЗQ | 1Q | |
| Office Business | 136.2 | 132.5 | 138.5 | 150.9 | 133.0 | 146.5 | 148.2 | 143.5 | |
| Professional Print Business | 47.5 | 49.6 | 51.1 | 55.8 | 49.0 | 52.2 | 53.9 | 53.4 | |
| Healthcare Business | 18.5 | 22.9 | 22.0 | 26.6 | 19.5 | 23.3 | 24.0 | 18.6 | |
| Industrial Business | 24.9 | 25.1 | 24.1 | 27.5 | 28.7 | 31.3 | 30.1 | 31.6 | |
| Optical Systems for Industrial Use | 7.0 | 5.7 | 6.1 | 10.5 | 11.7 | 11.5 | 11.1 | 10.1 | |
| Material • Components | 17.9 | 19.4 | 18.0 | 17.0 | 17.0 | 19.8 | 19.0 | 21.5 | |
| New business | 1.8 | 2.3 | 1.8 | 1.8 | 1.9 | 2.3 | 5.7 | 7.8 | |
| Bio-Healthcare | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 5.9 | |
| Others | 1.8 | 2.3 | 1.8 | 1.8 | 1.9 | 2.3 | 2.1 | 2.0 | |
| Corporate etc. | 0.4 | 0.3 | 0.2 | 0.3 | 0.1 | 0.2 | 0.3 | 0.3 | |
| Company overall | 229.1 | 232.8 | 237.7 | 262.9 | 232.4 | 255.8 | 262.2 | 255.2 | |

| [Operating Profit] | 1Q | 2Q | ЗQ | 4Q | 1Q | 2Q | ЗQ | 1Q |
|-----------------------------|------|------|------|------|------|-------|------|------|
| Office Business | 11.4 | 10.3 | 9.6 | 12.1 | 5.3 | 14.8 | 9.8 | 9.3 |
| Professional Print Business | 1.6 | 2.7 | 2.5 | 2.5 | 1.6 | 0.9 | 2.6 | 1.7 |
| Healthcare Business | 0.2 | 1.0 | 0.3 | 1.4 | -0.5 | 3.4 | 1.0 | -0.2 |
| Industrial Business | 3.4 | 3.0 | 10.4 | 5.3 | 6.1 | 5.9 | 5.6 | 6.8 |
| New Business | -2.9 | -2.2 | -2.4 | -2.4 | -2.7 | -3.2 | -4.4 | -5.1 |
| Corporate etc. | -4.8 | -5.2 | -4.4 | -3.0 | -1.1 | -10.0 | -5.9 | 3.1 |
| Company overall | 8.9 | 9.6 | 15.9 | 15.7 | 8.7 | 11.8 | 8.6 | 15.4 |



| Business S | egments for FY 2017 | Business S | egments for FY 2018 |
|--------------------------------|--|----------------------------------|---|
| Office Business | IT Service SolutionsOffice | Office Business | IT Service SolutionsOffice |
| Professional Print Business | Industrial Print Marketing Services Production Print | Professional Print Business | Industrial Print Marketing Services Production Print |
| Healthcare Business | Healthcare (Modality) Medical IT | Healthcare Business | Healthcare (Modality)Medical IT |
| Industrial Business | Optical Systems for Industrial Use Measuring Instruments Visual Solutions (Planetariums) Materials/Components Performance Materials (+OLED/Raw materials) Optical Components IJ Components | Industrial Business | Optical Systems for Industrial Use Measuring Instruments Visual Solutions (Planetariums) Materials/Components Performance Materials (+OLED/Raw materials) Optical Components J Components |
| New Businesses • Co | Growth Business SNew Business | New Businesses Corporate etc. | New Businesses Bio-healthcare Others(WPH, Monitoring, QOL, Digital manufacturing) Corporate, etc. |



•MCS (Managed Content Services): (Office Business)

The collective term given to services for centrally managing paper or digital documents, e-mails, forms, diagrams, and other such business content, and for building systems to properly use, store, and dispose of this content.

·IQ-501 (Intelligent Quality Optimizer): (Professional Print Business)

An optional unit that implements constant monitoring/control during printing to automate color management and front/back register control. This drastically cuts down on control times and increases production time.

•MGI (MGI Digital Graphic Technology): (Professional Print Business)

MGI is an output device manufacturer based in France. Konica Minolta formed a financial and strategic alliance with MGI in 2014, and MGI became a consolidated subsidiary in 2016. MGI provides unique products requiring special techniques such as decorative printing that are tailored to customer needs, and operates its global business in North America and Asia with a particular focus on Europe.

·DM (Digital Manufacturing): (New Business)

New manufacturing solutions based on ICT and the IoT that are not dependent on people, places, countries, or fluctuations.

•Workplace Hub (WPH): (New Business)

This is a platform that will become the base for the IoT business that Konica Minolta plans to focus on. In addition to MFP functions, a server is integrated to create a solution that drives efficiencies by reducing the overall costs of IT infrastructure management, providing real-time data-driven visibility of IT usage patterns that help to improve business processes. This will link people and data, and empower them to make smarter decisions and solve problems in the office.

•CRE Strategy (Corporate Real Estate Strategy): (Corporate)

A corporate strategy for a corporation to utilize its assets and real estate more efficiently in ways that benefit its business.

•S&LB (Sale and Leaseback): (Corporate)

A method for using assets more efficiently as part of a corporate strategy, in which a corporation sells one of its assets and then continues to use the asset by leasing it back.



Cautionary Statement:

The forecasts mentioned in this material are the results of estimations based on currently available information, and accordingly, contain risks and uncertainties. The actual results of business performance may sometimes differ from those forecasts due to various factors.

Remarks: Yen amounts are rounded to the nearest 100 million.